Printers that use human cells to create functional, living tissue may ultimately facilitate organ transplants for an aging population
Printers that use human cells to create functional, living tissue may ultimately facilitate organ transplants for an aging population
In recognition of its active partnering of 3D bioprinting technology with pharmaceutical companies, Organovo was named "Dealmaker of the Year" among San Diego firms for 2011 by Point Loma Nazarene University's School of Business. Federal Reserve branch President James Bullard spoke at the event, at which Organovo's leadership team gratefully accepted the award.
Say goodbye to donor lists and organ shortages. A biotech firm has created a printer that prints veins using a patients’ own cells. The device could potentially create whole organs in the future. “Right now we’re really good at printing blood vessels,” says Ben Shepherd, senior research scientist at regenerative-medicine company Organovo. “We printed 10 this week. We’re still learning how to best condition them to be good, strong blood vessels.”
Most organs in the body are filled with veins, so the ability to print vascular tissue is a critical building block for complete organs. The printed veins are about to start testing in animal trials, and eventually go through human clinical trials. If all goes well, in a few years you may be able to replace a vein that has deteriorated (due to frequent injections of chemo treatment, for example) with custom-printed tissue grown from your own cells.
The regenerative medicine company Organovo has made a prototype machine that can "print" new arteries by assembling living tissue. And they say that the same approach will one day allow doctors to print new organs for patients in need of a transplant.
Organovo creates a "bioink" of discrete cellular aggregates, each made up of many cells. These are used as a building block, as the bioprinter places these cell aggregates with high precision into a predetermined pattern. The cell aggregates all fuse together over time (within about 24 hours), creating a brand new piece of tissue. The tissue is held together by the same forces that the tissues in one's body use: cells attach to other cells, and cells produce collagen and attach to collagen. Cells know exactly how to behave once placed in the right orientation by the printer.
Think your printer produces lifelike images? Gabor Forgacs created one that prints the stuff of life -- specifically "bio ink," a liquid made up of cells. The cells cluster together and grow, and as he adds layers of bio ink, a 3D structure takes shape. Last year, Forgacs, 61, printed the first branching vascular tissue and successfully implanted a nerve graft into an animal. For now, he can do only simple tissues, such as blood vessels, but these advances are the first step to printing and growing replacement skin, muscle, and eventually organs.
Patients living with impaired or diseased organs typically have few options at their disposal. Surgical interventions can repair organs, but the worst cases require transplants, and sometimes right away.
But finding a compatible match can take time. Patients waiting for a donor are often in critical condition with their life hanging in the balance as they await a transplantable organ.
Enter what's being touted as a health care solution of the future: regenerative techniques that take a patient's own cells to re-grow tissues and organs at the bedside. By relying on a patient's own cells, the risk of an autoimmune rejection of the transplanted organ is greatly reduced.
The great hope of transplant surgeons is that they will, one day, be able to order replacement body parts on demand. At the moment, a patient may wait months, sometimes years, for an organ from a suitable donor. During that time his condition may worsen. He may even die. The ability to make organs as they are needed would not only relieve suffering but also save lives. And that possibility may be closer with the arrival of the first commercial 3D bio-printer for manufacturing human tissue and organs.
The new machine has been developed by Organovo, a company in San Diego that specialises in regenerative medicine, and Invetech, an engineering and automation firm in Melbourne, Australia. One of Organovo’s founders, Gabor Forgacs of the University of Missouri, developed the prototype on which the new 3D bio-printer is based. The first production models will soon be delivered to research groups which, like Dr Forgacs’s, are studying ways to produce tissue and organs for repair and replacement. At present much of this work is done by hand or by adapting existing instruments and devices.
A local biotech company has developed a machine with the ability to print tissue needed to build organs. While it might look like any other lab in San Diego's biotech corridor in Sorrento Valley, the projects being worked on at Organovo could be life-changing for millions of people."
Basically, I think we've put in one of the building blocks that will help change the transplant industry," said Richard Grant, vice president of Invetech.
Grant is referring to a special machine his company helped design for Organovo. The machine acts like a copy machine, but it prints cells to make human tissue and eventually organs.
A biomedical startup in San Diego is giving new form to tissue engineering, with the help of proprietary technology licensed from the University of Missouri and a 3D “bio-printer” capable of building human blood vessels and organs.
Organovo CEO Keith Murphy demonstrated the bio-printer for me several weeks ago, explaining that the technology was developed by Gabor Forgacs, a professor of biological physics at the University of Missouri. “The technology really sparked the germ of the company,” says Murphy, who previously spent 10 years at Thousand Oaks, CA-based Amgen.
Patients living with impaired or diseased organs typically have few options at their disposal. Surgical interventions can repair organs, but the worst cases require transplants, and sometimes right away.
But finding a compatible match can take time. Patients waiting for a donor are often in critical condition with their life hanging in the balance as they await a transplantable organ.
Enter what's being touted as a health care solution of the future: regenerative techniques that take a patient's own cells to re-grow tissues and organs at the bedside. By relying on a patient's own cells, the risk of an autoimmune rejection of the transplanted organ is greatly reduced.
A San Diego company is developing technology to "print" artificial tissues. The long-term goal is to solve problems in medical research that can't be solved otherwise, said Keith Murphy, CEO of the company, Organovo.
3D printers are an emerging technology with a wide variety of applications. Like Organovo's equipment, they build 3D objects by laying down two-dimensional layers one on top of the other. They typically use plaster, cornstarch or resins to create objects, and are most often used in rapid prototoyping, for footwear, jewelry, industrial design, architecture, automotive, aerospace, dental, and medical industries.
Organovo uses 3D printing technology in the biological context.
Organovo is working at the cutting edge of regenerative medicine. The San Diego—based company is developing organ-printing technology that CEO Keith Murphy says will usher in a new age of "tissue on demand," built in the lab. Using droplets of "bio ink" made of cells taken from a patient's body, Organovo's bioprinter lays down a three-dimensional pattern that assembles itself into a new organ. The company is focusing first on building arteries to be used in bypass procedures -- initially for the legs, and eventually for the heart.
With venture capital funding all but dried up for many life sciences startups, some have turned to agencies that specialize in navigating complex government databases and matching businesses with sometimes lucrative grants.
San Diego company Organovo has been able to obtain National Institutes of Health (NIH) funding through the Small Business Innovation Research (SBIR) program due to the strength of its novel 3D Bioprinting technologies.